Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	7/11/2003 7:00:09 AM
From: nigel bates	of 625

ROCKVILLE, Md., July 11 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) announced today that it has received a clinical trial exemption (CTX) from the United Kingdom's Medicines and Healthcare products Regulatory Agency allowing the Company to begin clinical development of an agonistic human monoclonal antibody to TRAIL Receptor-2 (TRAIL-R2 mAb, HGS- ETR2). The Company now plans to proceed with a Phase 1 open-label, dose- escalating study in the United Kingdom to evaluate the safety and pharmacology of TRAIL-R2 mAb in patients with advanced tumors.... Message 19101271 ...and it is the CAT mAB, not the Kirin one.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next